Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 10/20 | 0.35 |
| ▸ | AGPAT2 | O15120 | 1/20 | 0.32 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.32 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.31 |
| ▸ | RAF1 | P04049 | 1/20 | 0.31 |
| ▸ | BRAF | P15056 | 1/20 | 0.31 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.31 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.31 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.31 |
| ▸ | CDK9 | P50750 | 1/20 | 0.31 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.31 |
| ▸ | SMO | Q99835 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23770724 | 0.90 | MAP4K1 (0.34) | MAP4K1SCN9ACCNT1CDK9P2RX7 | |
| SCHEMBL23770574 | 0.88 | CCNT1 (0.31) | MAP4K1CCNT1 | |
| SCHEMBL23770808 | 0.86 | HTR3E (0.38) | ABL1SCN9ACCNT1CDK9 | |
| SCHEMBL23770850 | 0.85 | LRRK2 (0.33) | ABL1LRRK2 | |
| SCHEMBL23770831 | 0.84 | ABL1 (0.33) | ABL1AGPAT2 | |
| SCHEMBL23770677 | 0.84 | ABL1 (0.36) | ABL1RAF1BRAFCCNT1CDK9 | |
| SCHEMBL23770455 | 0.83 | CCNT1 (0.32) | SCN9ACCNT1CDK9P2RX7 | |
| SCHEMBL23770489 | 0.81 | HSD11B1 (0.33) | GRIN2BMAP4K1LRRK2CCNT1 | |
| SCHEMBL19925201 | 0.81 | GHSR (0.38) | ABL1MAP4K1RAF1BRAFLRRK2 | |
| SCHEMBL29464868 | 0.81 | GHSR (0.38) | ABL1MAP4K1RAF1BRAFLRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3504194-B1 | N-(PYRIDIN-2-YL)PYRIDINE-SULFONAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | NOVARTIS AG (CH) | 2021-08-18 | — | — | EP | disclosed |